Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study. (Q51305217)
Jump to navigation
Jump to search
scientific article published on 7 April 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study. |
scientific article published on 7 April 2015 |
Statements
1 reference
Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study. (English)
1 reference
1 reference
Takashi Kadowaki
1 reference
Masakazu Haneda
1 reference
Yasuo Terauchi
1 reference
Atsushi Taniguchi
1 reference
Kazuki Koiwai
1 reference
Henning Rattunde
1 reference
Hans J Woerle
1 reference
Uli C Broedl
1 reference
7 April 2015
1 reference
32
1 reference
306-318
1 reference
4
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference